Unknown PHASE2 INTERVENTIONAL 2-arm NCT02630277

Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN (ELYSIAN)

Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept Injection (ELYSIAN)

Sponsor: Valley Retina Institute

Conditions Proliferative Diabetic Retinopathy

Interventions Aflibercept

Updated 7 times since 2017 Last updated: Dec 10, 2015 Started: Jan 31, 2016 Primary completion: Jan 31, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Proliferative Diabetic Retinopathy and is currently ongoing. Valley Retina Institute leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Feb 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Valley Retina Institute

Data source: Valley Retina Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.